Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Dissent Expected at September Fed Meeting as Hawks and Doves Clash

Dissent Expected at September Fed Meeting as Hawks and Doves Clash

ChaincatcherChaincatcher2025/08/14 03:22
Show original

According to ChainCatcher, citing Jin10, Ethan Harris, former chief economist at Bank of America Securities, stated that the days of a unified Federal Reserve are gone for good. The dissent in support of rate cuts from Waller and Bowman, both appointed by President Trump and both supporting rate cuts in July, has “broken the harmony.” He expects that before the September meeting, there will be intense debate between hawks and doves, adding uncertainty to the rate cut decision. Stephen Ricchiuto, chief economist at Mizuho Securities, pointed out that neither the hawks, who support keeping rates unchanged, nor the doves, who favor easing, hold a majority; most Fed officials currently take a centrist stance.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56